Study on the Relationship Between PTPRO Methylation in Plasma and Efficacy Neoadjuvant Chemotherapy in Patients with Early Breast Cancer

• Published in: International journal of women's health Vol. 15; pp. 1673 - 1680
• Main Authors: Liu, Xiang-Wei, Hong, Mei-Juan, Qu, Yan-Yu
• Format: Journal Article
• Language: English
• Published: Dove Medical Press Limited 30.11.2023; Dove; Dove Medical Press
• Subjects: Adjuvant treatment; Breast cancer; Cancer; Cancer patients; Care and treatment; liquid biopsy; Methylation; neoadjuvant chemotherapy; Oncology, Experimental; Original Research; ptpro; Canada; China
• ISSN: 1179-1411; 1179-1411
• DOI: 10.2147/IJWH.S428038

Objective: This study aimed to explore the correlation between PTPRO methylation in plasma and the efficacy of neoadjuvant chemotherapy (NAC) for early breast cancer (BC). Methods: Eighty-two patients with early BC undergoing NAC were included. PTPRO methylation status in plasma before and after NAC was detected using methylation-specific PCR and the relationship between PTPRO methylation and NAC efficacy was analyzed. Results: The rate of pathologic complete response (pCR) was only 25.0% (12/48) in patients with positive PTPRO methylation result before NAC, but 61 0.8% (21/34) in pre-NAC methylation-negative patients (OR = 0.24, 95% CI: 0.09-0.65, P = 0.005). In addition, the pCR rate was 12.1% (4/33) in patients with positive PTPRO methylation results both before and after NAC, but 53.3% (8/15) in patients with pre-NAC positive methylation and post-NAC negative methylation results (OR = 0.12, 95% CI: 0.03-0.52, P = 0.004). Conclusion: Plasma PTPRO methylation is a potential biomarker for predicting the efficacy of NAC in early BC. Keywords: breast cancer, neoadjuvant chemotherapy, PTPRO, methylation, liquid biopsy